Spots Global Cancer Trial Database for iressa
Every month we try and update this database with for iressa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer | NCT00234442 | Brain Neoplasms Non Small Cell ... | Iressa (Gefitin... | 18 Years - | AstraZeneca | |
| Open-Label Extension of Other SZ1839 (Iressa) Trials | NCT00635973 | Cancer | Gefitinib (Ires... | 18 Years - | AstraZeneca | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients | NCT00206492 | Breast Cancer | Iressa Tamoxifen | 18 Years - | Baylor Breast Care Center | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin | NCT00054691 | Skin Cancer | Iressa | 18 Years - | M.D. Anderson Cancer Center | |
| An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma | NCT00787410 | Mesothelioma | ZD1839 | 18 Years - | AstraZeneca | |
| Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer | NCT00181688 | Ovarian Cancer Peritoneal Carc... Tubal Carcinoma | Iressa (ZD1839) Arimidex (Anast... | 18 Years - | Massachusetts General Hospital | |
| Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer | NCT00319787 | Locally Advance... | Iressa | 18 Years - 80 Years | AstraZeneca | |
| Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients | NCT00206492 | Breast Cancer | Iressa Tamoxifen | 18 Years - | Baylor Breast Care Center | |
| Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer | NCT00234442 | Brain Neoplasms Non Small Cell ... | Iressa (Gefitin... | 18 Years - | AstraZeneca | |
| Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer | NCT00681967 | Head and Neck C... | Gefitinib Gefitinib | 18 Years - | AstraZeneca | |
| Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) | NCT00215202 | Nonresectable A... | Iressa (ZD1839) | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma | NCT00787410 | Mesothelioma | ZD1839 | 18 Years - | AstraZeneca | |
| Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer | NCT00681967 | Head and Neck C... | Gefitinib Gefitinib | 18 Years - | AstraZeneca | |
| Gefitinib Usage and Outcomes in Routine Treatment | NCT01818947 | Lung Cancer | 18 Years - | AstraZeneca | ||
| A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer | NCT00238628 | Lung Cancer | Bexarotene Iressa | 18 Years - | Stanford University | |
| Iressa Study in Patients With Salivary Gland Cancer | NCT00509002 | Salivary Gland ... | Gefitinib | - | M.D. Anderson Cancer Center | |
| Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer | NCT00352105 | Head and Neck C... | cisplatin fluorouracil Iressa hyperfractionat... | 18 Years - | Case Comprehensive Cancer Center | |
| Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer | NCT00173875 | Non-Small Cell ... | Iressa | 20 Years - | National Taiwan University Hospital | |
| Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia | NCT00130702 | Myelogenous Leu... | gefitinib | 18 Years - | Dana-Farber Cancer Institute | |
| High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations | NCT00372515 | Non-Small Cell ... | Gefitinib | 18 Years - | Dana-Farber Cancer Institute | |
| Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer | NCT00352105 | Head and Neck C... | cisplatin fluorouracil Iressa hyperfractionat... | 18 Years - | Case Comprehensive Cancer Center | |
| Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer | NCT00173875 | Non-Small Cell ... | Iressa | 20 Years - | National Taiwan University Hospital | |
| Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | NCT00479089 | Bladder Cancer | Docetaxel ZD1839 Dexamethasone | - | M.D. Anderson Cancer Center | |
| Open Label Trial to Assess Iressa in Prostate Cancer Patients | NCT00635856 | Prostate Cancer | Gefitinib | 18 Years - | AstraZeneca | |
| Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer | NCT00137761 | Metastatic Panc... | ZD 1839 Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | NCT00479089 | Bladder Cancer | Docetaxel ZD1839 Dexamethasone | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
